ネオゲンの株は 分析者が目標値を下げると 衝撃を受けています 内部からの買い物にもかかわらずです Neogen's stock takes a hit as analysts lower price targets, despite insider buying.

Neogenの株価は格下げに直面し,Guggenheimは目標価格を10.00ドルに下げたが",買い"の評価を維持し,Piper Sandlerは目標値を5.00ドルに下げて"中立"と評価した. Neogen's stock has faced a downgrade with Guggenheim lowering its price target to $10.00 but maintaining a "buy" rating, while Piper Sandler dropped its target to $5.00 and rated it "neutral." 最新の四半期における53.56%の否定的なネット余白にもかかわらず,地理系に基づく診断を専門とするネオゲンは,最近,インサイダーが83,500株を購入している. Despite a negative net margin of 53.56% in the latest quarter, Neogen, which specializes in genomics-based diagnostics, has seen insiders buy 83,500 shares recently. 現在,平均12ヶ月の価格目標は8.62ドルで,175ドルから27.26%減少し,反射市場とパフォーマンスシフトを反映している. The average 12-month price target is now $8.62, down 27.26% from $11.85, reflecting market and performance shifts.